Table 4.
All the QM statistics for whether the moderators have a significant effect on clinical response rate
| (A) Clinical response week 8 | |||
| Moderator | QM | df | p |
| Number of center | 0.0003 | 1 | 0.9506 |
| Severity | 1.226 | 1 | 0.2682 |
| (B) Clinical response week 16 | |||
| Moderator | QM | df | p |
| Study design | 0.9954 | 1 | 0.3184 |
| Number of center | 1.6779 | 2 | 0.4322 |
| Prior anti-TNFα | 0.3354 | 1 | 0.5625 |
| Prior more than two anti-TNFα | 0.0167 | 1 | 0.8971 |
| Prior VDZ | 0.0059 | 1 | 0.9387 |
| Prior TOF | 0.063 | 1 | 0.8019 |
| Severity | 3.0222 | 2 | 0.2207 |
| Concomittant IM | 0.0733 | 1 | 0.7865 |
| Concomittant steroid | 0.2718 | 1 | 0.6021 |
| Publish style | 0.9954 | 1 | 0.3184 |
| (C) Clinical response month 6 | |||
| Moderator | QM | df | p |
| Severity | 0.0136 | 1 | 0.9073 |
| Publish style | 0.7295 | 1 | 0.3931 |
QM: test statistic for the omnibus test of moderators
TNF: tumor necrosis factor
df: degrees of freedom
VDZ: vedolizumab
TOF: tofacitinib
IM: immunomodulator